Navigation Links
XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting

Trial Included One of the Most Challenging Patient Populations Studied of Any Drug-Eluting Stent (DES) Clinical Trial

BARCELONA and MENLO PARK, Calif., May 22, 2007 /PRNewswire-FirstCall/ -- XTENT, Inc. announces positive six-month follow-up data from the CUSTOM II clinical trial, which assessed the safety and efficacy of the company's investigational Custom NX(R) drug-eluting stent (DES) system for the treatment of long and multiple lesions in patients with coronary artery disease.

The single-arm prospective study evaluated the use of CUSTOM NX in patients with long lesions, defined as greater than 20mm, and patients with two lesions. Of the 100 patients enrolled, 69 patients were enrolled in the long lesion arm, and 31 patients were enrolled in the two lesion arm of the study. Up to two customizable stent deployments of up to 60mm total length were evaluated in the study. The primary endpoint was Major Adverse Cardiac Events (MACE) at six months, with clinical follow-up at one, six and 12 months, then annually for five years. Angiographic and intravascular ultrasound (IVUS) follow-up was conducted at six months. The anticoagulation regimen was clopidogrel for a minimum of three months plus aspirin.

At six-month follow-up, the MACE rate was 9%. Early adverse events (in hospital) occurred in five patients, including four myocardial infarctions and one death. At six months, four additional patients (4%) underwent target lesion revascularization. Angiographic and IVUS results demonstrated in-stent late loss was 0.31mm; in-segment late loss was 0.22mm; binary restenosis rate was 7.5%; and the percentage of neointimal volume was 3.3%.

"These data are particularly encouraging considering CUSTOM II enrolled one of the most difficult-to-treat patient populations ever studied in a DES trial and also mirrored the complex disease profile physicians are most likely to see among patients presenting tod
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/17/2014)... 17, 2014 , ... a hub of information concerning the biopharmaceutical Group,s national and ... further addition to the recently launched institutional website that is ... been enriched by a new chapter in the fascinating story ... richly detailed and panoramic hub on the world of clinical ...
(Date:12/17/2014)... Dec. 17, 2014 PCCA received the ... ( http://bit.ly/1382OkS ) program seal for best practices ... program highlights medical practices, materials and goods that ... Children affected by autism often have ... exacerbated by ingredients found in food and medicine ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the ... Estimates and Forecasts, 2012-2018"  report to their offering. ... by 2016. The North America ... while Europe claims approximately 25% ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4
... Pa., Aug. 9, 2011 Styron, the global ... rubber, announced an addition to its EMERGE™ Advanced ... PC/PET 9100CR Advanced Resin is a polycarbonate ... for medical equipment housing applications. (Logo: ...
... Inc. (Nasdaq: CYBX ) today announced that the company ... 2011 of its fiscal year ending April 27, 2012, on Thursday, ... conduct a conference call to discuss those results on the same ... Fiscal Year 2012 First Quarter Results Conference Call Instructions ...
Cached Medicine Technology:Styron Introduces Chemical Resistance Blends for Medical Housings 2Cyberonics to Report Fiscal Year 2012 First Quarter Results and Host Conference Call on August 25, 2011 2
(Date:12/17/2014)... News) -- Expectant parents should leave prenatal picture-taking to ... Use of ultrasound imaging and heartbeat monitors to ... the agency warns. "Although there is a ... imaging and heartbeat monitors, prudent use of these devices ... an FDA biomedical engineer, said in an agency news ...
(Date:12/17/2014)... Amy Norton HealthDay Reporter ... long been believed to improve overall health, but a growing ... the heart, a new review finds. In fact, the ... brisk walking, said lead researcher Paula Chu, a doctoral candidate ... review, of 37 clinical trials, found that people randomly assigned ...
(Date:12/15/2014)... NV (PRWEB) December 15, 2014 Veretekk.com, ... company, JM Ocean Avenue. JM Ocean Avenue has ... the Veretekk online automated marketing system. JM Ocean ... June 2014 merger of Ocean Avenue and JM International, ... than $2 Billion per year company. , “After nearly ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 OutMarket ... today released “ Social Media Cheat Sheets ,” a ... community that drives results on the top ten social ... program. It helps drive awareness, engagement, and customer service. ... marketers to make an impact on new networks and ...
(Date:12/15/2014)... Dallas,TX (PRWEB) December 15, 2014 The increase ... is one of the main factors which is contributing to ... used for the diagnosis and treatment of hearing loss and ... comprises of three parts - microphone, speaker and amplifier. The ... growth rate of 6.01% during the period from 2014 to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... with good health and vitality. However, just a small amount ... D. //It doesn't take much sunlight to make all the ... it takes to get a suntan. ,Recently, a study ... UV light (UVL) tanning behavior. For the study, researchers at ...
... survey conducted by Synovate India and sponsored by Colgate-Palmolive (India) ... and the latest toothpaste available in the market, //the level ... of those surveyed admitted that they have never been to ... that poor oral hygiene practices are resulting in a myriad ...
... global burden imposed by the widespread incidence of AIDS, ... //It has been estimated that one in every six ... initiative would focus on the efficacy of herbal remedies ... were considered out of which three have been approved. ...
... spatial processing, memory, and cognitive proficiency are consequences of ... than the general population,// yet the possible neurocognitive effects ... despite evidence that long-term smoking is associated with neurocognitive ... A research team from ...
... Florida doctors claim that some head and neck cancer patients ... a CT scan.// This scan can predict whether the cancer ... ,These findings were presented at the annual meeting of the ... M.D., a resident in radiation oncology at the UF Shands ...
... gynecomastia, and loss of sexual interest have often been ... reported in men who are long-term alcohol users,// with ... ethanol might cause gonadal disorders, including structural testicular changes ... T, which might be involved in the hypogonadism and ...
Cached Medicine News:Health News:Detrimental Effect Of Chronic Alcoholism On Male Fertility 2
The Pedia-Trake® is designed to reduce the possibility of over penetration., ,Pedia-Trake® is used to establish an emergency airway in pediatric patients more than one year old....
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Used for emergency airway access when conventional endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
... steel. Lamp supplied with blade. Rusch ... quality standard incandescent laryngoscope blades. The ... continually refined through many years of ... maintenance requirements. They are manufactured to ...
Medicine Products: